Molecular genetics diagnostic company Mainz Biomed N.V. (NASDAQ:MYNZ) said on Tuesday that it has applied to the US Food and Drug Administration (FDA) for Breakthrough Device Designation for its next-generation colorectal cancer (CRC) screening test.
The test has demonstrated 97% sensitivity for cancer and 88% for advanced adenomas, with high specificity.
This designation, if granted, could expedite approval for the test that combines the Fecal Immunochemical Test (FIT) with mRNA biomarkers and AI analysis.
HELP Therapeutics' HiCM-188 IND application receives US FDA approval
Ananda's cannabinoid medicines to feature in NHS epilepsy trials
AstraZeneca's Wainzua recommended for EU approval
Astellas Pharma's VYLOY receives US FDA approval
Accord Healthcare wins CHMP approval for Stelara biosimilar Imuldosa
Ionis and AstraZeneca's WAINZUA recommended for EU approval
Novartis receives positive CHMP opinion for Kisqali
Viatris signs exclusive licensing agreement with Lexicon Pharmaceuticals
Adicet Bio receives FDA clearance to expand ADI-001 trials to additional autoimmune diseases
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
SystImmune receives FDA clearance for Phase 1 trial of novel AML therapy
Accord BioPharma's IMULDOSA receives US FDA approval to treat chronic inflammatory conditions
PTC Therapeutics' sepiapterin receives US FDA target regulatory action date
RedHill Biopharma's opaganib selected for Ebola treatment development by BARDA